{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T04:20:10Z","timestamp":1775708410340,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Robenacoxib (Onsior\u2122) is a non-steroidal anti-inflammatory drug developed for canine and feline use for the control of pain and inflammation. It is available as both tablets and solution for injection.<\/jats:p><jats:p>The objective of this study was to evaluate the safety of the interchangeable use of commercially available robenacoxib formulations when administered to cats orally using 6 mg tablets and subcutaneously using a solution for injection containing 20 mg\/mL. Thirty-four na\u00efve healthy 4-month old cats were enrolled in this 37-day study and were randomized to four groups (three robenacoxib and one control). One robenacoxib group received the maximum recommended dose (MRD) rate of each formulation, while the other two received two and three times this dose rate. The cats underwent three 10-day treatment cycles comprised of seven days of once daily oral administration followed by three days of subcutaneous administration. The third cycle was followed by an additional seven days of oral treatment. The control group received oral empty gelatin capsules or subcutaneous saline injections. Assessment of safety was based on general health observations, clinical observations, physical, ophthalmic, electrocardiographic and neurological examinations, clinical pathology evaluations, food consumption, body weight, and macroscopic and microscopic examinations. Blood samples were collected for toxicokinetic evaluation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Blood concentrations of robenacoxib confirmed systemic exposure of all treated cats. All cats were in good health through study termination and there were no serious adverse events during the study. There were no changes in body weight, food consumption, ophthalmic, physical or neurological examinations during the study. Treatment-related abnormalities were of low occurrence at all doses and included injection site changes (transient edema with minimal or mild, subacute\/chronic inflammation histologically) and prolongation of the QT interval. These findings were consistent with previously observed findings in studies with robenacoxib administered separately orally or subcutaneously in cats. Thus, there were no adverse effects that could be attributed specifically to the interchangeable use of oral and injectable robenacoxib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This 37-day laboratory study supports the safety of interchanging robenacoxib injection at a daily dose of 2 mg\/kg with robenacoxib tablets at a daily dose of 1 mg\/kg, or vice versa.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12917-020-02553-7","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T09:02:56Z","timestamp":1601283776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety evaluation of the interchangeable use of robenacoxib in commercially-available tablets and solution for injection in cats"],"prefix":"10.1186","volume":"16","author":[{"given":"Mark C.","family":"Heit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Jay","family":"Stallons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Seewald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caryn M","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line E.","family":"Toutain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen B.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Helbig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"issue":"5","key":"2553_CR1","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.cvsm.2015.04.007","volume":"45","author":"SH Berry","year":"2015","unstructured":"Berry SH. Analgesia in the Perioperative Period. Vet Clin North Am Small Anim Pract. 2015;45(5):1013\u201327. .","journal-title":"Vet Clin North Am Small Anim Pract"},{"issue":"6","key":"2553_CR2","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.cvsm.2008.09.002","volume":"38","author":"MG Papich","year":"2008","unstructured":"Papich MG. An update on nonsteroidal anti-inflammatory drugs (NSAIDs) in small animals. Vet Clin North Am Small Anim Pract. 2008;38(6):1243\u201366 (vi.). .","journal-title":"Vet Clin North Am Small Anim Pract"},{"issue":"4","key":"2553_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0195-5616(08)70006-8","volume":"30","author":"A Livingston","year":"2000","unstructured":"Livingston A. Mechanism of action of nonsteroidal anti-inflammatory drugs. Vet Clin North Am Small Anim Pract. 2000;30(4):773\u201381 (vi.). .","journal-title":"Vet Clin North Am Small Anim Pract"},{"issue":"1","key":"2553_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.tvjl.2013.12.020","volume":"200","author":"TW Kim","year":"2014","unstructured":"Kim TW, Lebkowska-Wieruszewska B, Owen H, Yun HI, Kowalski CJ, Giorgi M. Pharmacokinetic profiles of the novel COX-2 selective inhibitor cimicoxib in dogs. Vet J. 2014;200(1):77\u201381. .","journal-title":"Vet J"},{"issue":"3","key":"2553_CR5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1365-2885.2011.01320.x","volume":"35","author":"JN King","year":"2012","unstructured":"King JN, Hotz R, Reagan EL, Roth DR, Seewald W, Lees P. Safety of oral robenacoxib in the cat. J Vet Pharmacol Ther. 2012;35(3):290\u2013300.","journal-title":"J Vet Pharmacol Ther"},{"issue":"7","key":"2553_CR6","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.2460\/ajvr.2005.66.1278","volume":"66","author":"ME McCann","year":"2005","unstructured":"McCann ME, Rickes EL, Hora DF, Cunningham PK, Zhang D, Brideau C, Black WC, Hickey GJ. In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in cats with lipopolysaccharide-induced pyrexia. Am J Vet Res. 2005;66(7):1278\u201384. .","journal-title":"Am J Vet Res"},{"issue":"1","key":"2553_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2885.2008.00962.x","volume":"32","author":"JN King","year":"2009","unstructured":"King JN, Dawson J, Esser RE, Fujimoto R, Kimble EF, Maniara W, Marshall PJ, O\u2019Byrne L, Quadros E, Toutain PL, et al. Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2. J Vet Pharmacol Ther. 2009;32(1):1\u201317.","journal-title":"J Vet Pharmacol Ther"},{"issue":"4","key":"2553_CR8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1365-2885.2008.01043.x","volume":"32","author":"ES Roberts","year":"2009","unstructured":"Roberts ES, Van Lare KA, Marable BR, Salminen WF. Safety and tolerability of 3-week and 6-month dosing of Deramaxx (deracoxib) chewable tablets in dogs. J Vet Pharmacol Ther. 2009;32(4):329\u201337.","journal-title":"J Vet Pharmacol Ther"},{"issue":"5","key":"2553_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/j.1365-2885.2010.01165.x","volume":"33","author":"SR Cox","year":"2010","unstructured":"Cox SR, Lesman SP, Boucher JF, Krautmann MJ, Hummel BD, Savides M, Marsh S, Fielder A, Stegemann MR. The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs. J Vet Pharmacol Ther. 2010;33(5):461\u201370.","journal-title":"J Vet Pharmacol Ther"},{"issue":"1","key":"2553_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12917-016-0827-0","volume":"12","author":"S King","year":"2016","unstructured":"King S, Roberts ES, King JN. Evaluation of injectable robenacoxib for the treatment of post-operative pain in cats: results of a randomized, masked, placebo-controlled clinical trial. BMC Vet Res. 2016;12(1):215.","journal-title":"BMC Vet Res"},{"key":"2553_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12917-015-0391-z","volume":"11","author":"C Speranza","year":"2015","unstructured":"Speranza C, Schmid V, Giraudel JM, Seewald W, King JN. Robenacoxib versus meloxicam for the control of peri-operative pain and inflammation associated with orthopaedic surgery in cats: a randomised clinical trial. BMC Vet Res. 2015;11:79.","journal-title":"BMC Vet Res"},{"key":"2553_CR12","unstructured":"US Food and Drug Administration Freedom of Information Summary: Original New Animal Drug Application NADA 141\u2013320 (Onsior Robenacoxib Tablets for Cats) 2011."},{"key":"2553_CR13","unstructured":"US Food and Drug Administration Freedom of Information Summary: Original New Animal Drug Application NADA 141\u2013443 (Onsior Robenacoxib Injection Cats) 2015."},{"key":"2553_CR14","unstructured":"European Medicines Agency: European Public Assessment Report, Onsior Summary of Product Characteristics 2008."},{"key":"2553_CR15","unstructured":"Veterinary International Conference on Harmonization (VICH) Guideline 43: Target Animal Safety for Veterinary Pharmaceutical Products http:\/\/www.vichsec.org\/guidelines\/pharmaceuticals\/pharma-safety\/pharma-target-animal-safety.html."},{"issue":"1","key":"2553_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/s12917-017-1269-z","volume":"13","author":"CE Toutain","year":"2017","unstructured":"Toutain CE, Heit MC, King SB, Helbig R. Safety evaluation of the interchangeable use of robenacoxib (Onsior) tablets and solution for injection in dogs. BMC Vet Res. 2017;13(1):359.","journal-title":"BMC Vet Res"},{"issue":"3","key":"2553_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nrd1034","volume":"2","author":"RJ Flower","year":"2003","unstructured":"Flower RJ. The development of COX2 inhibitors. Nat Rev Drug Disc. 2003;2(3):179\u201391.","journal-title":"Nat Rev Drug Disc"},{"issue":"13","key":"2553_CR18","doi-asserted-by":"publisher","first-page":"7563","DOI":"10.1073\/pnas.96.13.7563","volume":"96","author":"TD Warner","year":"1999","unstructured":"Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999;96(13):7563\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2553_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/j.1601-0825.2004.01024.x","volume":"10","author":"JV Bagan","year":"2004","unstructured":"Bagan JV, Thongprasom K, Scully C. Adverse oral reactions associated with the COX-2 inhibitor rofecoxib. Oral Dis. 2004;10(6):401\u20133.","journal-title":"Oral Dis"},{"issue":"1","key":"2553_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1258\/0023677011911345","volume":"35","author":"DB Morton","year":"2001","unstructured":"Morton DB, Jennings M, Buckwell A, Ewbank R, Godfrey C, Holgate B, Inglis I, James R, Page C, Sharman I, et al. Refining procedures for the administration of substances. Report of the BVAAWF\/FRAME\/RSPCA\/UFAW Joint Working Group on Refinement. British Veterinary Association Animal Welfare Foundation\/Fund for the Replacement of Animals in Medical Experiments\/Royal Society for the Prevention of Cruelty to Animals\/Universities Federation for Animal Welfare. Lab Anim. 2001;35(1):1\u201341. .","journal-title":"Lab Anim"},{"issue":"11","key":"2553_CR21","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.2460\/ajvr.1999.60.11.1426","volume":"60","author":"WA Ware","year":"1999","unstructured":"Ware WA, Christensen WF. Duration of the QT interval in healthy cats. Am J Vet Res. 1999;60(11):1426\u20139. .","journal-title":"Am J Vet Res"},{"issue":"6","key":"2553_CR22","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/00004714-199812000-00011","volume":"18","author":"MD Drici","year":"1998","unstructured":"Drici MD, Wang WX, Liu XK, Woosley RL, Flockhart DA. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol. 1998;18(6):477\u201381.","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"2553_CR23","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/cvr\/27.12.2186","volume":"27","author":"L Carlsson","year":"1993","unstructured":"Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc Res. 1993;27(12):2186\u201393. .","journal-title":"Cardiovasc Res"},{"issue":"S1","key":"2553_CR24","first-page":"149","volume":"38","author":"A Panteri","year":"2015","unstructured":"Panteri A, Deurinck M, Seewald W, Gerber S, King JN, Desevaux C. Safety of intravenous Robenacoxib (Onsior) in cats. J Vet Pharmacol Ther. 2015;38(S1):149.","journal-title":"J Vet Pharmacol Ther"},{"issue":"1","key":"2553_CR25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.tvjl.2011.11.026","volume":"193","author":"M Kamata","year":"2012","unstructured":"Kamata M, King JN, Seewald W, Sakakibara N, Yamashita K, Nishimura R. Comparison of injectable robenacoxib versus meloxicam for peri-operative use in cats: results of a randomised clinical trial. Vet J. 2012;193(1):114\u20138. .","journal-title":"Vet J"},{"issue":"1","key":"2553_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1365-2885.2008.01016.x","volume":"32","author":"JM Giraudel","year":"2009","unstructured":"Giraudel JM, King JN, Jeunesse EC, Lees P, Toutain PL. Use of a pharmacokinetic\/pharmacodynamic approach in the cat to determine a dosage regimen for the COX-2 selective drug robenacoxib. J Vet Pharmacol Ther. 2009;32(1):18\u201330.","journal-title":"J Vet Pharmacol Ther"},{"issue":"3","key":"2553_CR27","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2460\/ajvr.74.3.465","volume":"74","author":"JN King","year":"2013","unstructured":"King JN, Jung M, Maurer MP, Schmid VB, Seewald W, Lees P. Effects of route of administration and feeding schedule on pharmacokinetics of robenacoxib in cats. Am J Vet Res. 2013;74(3):465\u201372. .","journal-title":"Am J Vet Res"},{"key":"2553_CR28","doi-asserted-by":"crossref","unstructured":"King S, Roberts ES, Roycroft LM, King JN. Evaluation of oral robenacoxib for the treatment of postoperative pain and inflammation in cats; results of a randomized clinical trial. ISRN Veterinary Science, 2012 ID 794148, 1\u20138.","DOI":"10.5402\/2012\/794148"},{"key":"2553_CR29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.tvjl.2012.02.008","volume":"193","author":"T Sano","year":"2012","unstructured":"Sano T, King JN, Seewald W, Sakakibara N, Okumura M. Comparison of oral robenacoxib and ketoprofen for the treatment of acute pain and inflammation associated with musculoskeletal disorders in cats: a randomised clinical trial. Vet J. 2012;193:397\u2013403.","journal-title":"Vet J"},{"key":"2553_CR30","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1177\/1098612X15590870","volume":"18","author":"JN King","year":"2015","unstructured":"King JN, King S, Budsberg SC, Lascelles BDX, Bienhoff SE, Roycroft LM, Roberts ES. Clinical safety of robenacoxib in feline osteoarthritis: results of a randomized, blinded, placebo-controlled clinical trial. J Feline Med Surg. 2015;18:632\u201342. .","journal-title":"J Feline Med Surg"},{"key":"2553_CR31","unstructured":"US Food. and Drug Administration Code of Federal Regulations Title 21, Part 58, Good Laboratory Practice for Nonclinical Laboratory Studies https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?CFRPart=58."},{"key":"2553_CR32","unstructured":"Organisation for Economic Cooperation and Development (OECD) Series on Principles of Good Laboratory Practice (GLP) and Compliance Monitoring http:\/\/www.oecd.org\/chemicalsafety\/testing\/oecdseriesonprinciplesofgoodlaboratorypracticeglpandcompliancemonitoring.htm."},{"key":"2553_CR33","unstructured":"U.S. Department of Agriculture\u2019s Animal Welfare Act, 9 CFR Parts 1, 2 and 3 https:\/\/www.nal.usda.gov\/awic\/final-rules-animal-welfare-9-cfr-parts-1-2-and-3."},{"key":"2553_CR34","unstructured":"Guide for the Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources. Washington, D.C: National Academy Press; 1996."},{"key":"2553_CR35","unstructured":"US National. Institutes of Health Office of Laboratory Animal Welfare [https:\/\/grants.nih.gov\/grants\/olaw\/olaw.html]."},{"issue":"4","key":"2553_CR36","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1080\/01926230290105721","volume":"30","author":"JR Latendresse","year":"2002","unstructured":"Latendresse JR, Warbrittion AR, Jonassen H, Creasy DM. Fixation of testes and eyes using a modified Davidson\u2019s fluid: comparison with Bouin\u2019s fluid and conventional Davidson\u2019s fluid. Toxicol Pathol. 2002;30(4):524\u201333.","journal-title":"Toxicol Pathol"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-020-02553-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-020-02553-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-020-02553-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T23:17:12Z","timestamp":1723677432000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-020-02553-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2553"],"URL":"https:\/\/doi.org\/10.1186\/s12917-020-02553-7","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,25]]},"assertion":[{"value":"13 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study design was based on VICH GL43 Target Animal Safety Guidelines for Veterinary Pharmaceutical Products and the study protocol was approved by the Institutional Animal Care and Use Committee of MPI Research Inc, (Mattawan, Michigan, US).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are employees of Elanco Animal Health or were at the time of the study and\/or manuscript submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"355"}}